Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC cut its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,081 shares of the biopharmaceutical company’s stock after selling 987 shares during the period. Fidelis Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $641,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in BMY. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. ORG Wealth Partners LLC bought a new position in shares of Bristol-Myers Squibb in the third quarter worth $34,000. LGT Financial Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares in the last quarter. MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the second quarter worth about $39,000. Finally, Beach Investment Counsel Inc. PA bought a new position in Bristol-Myers Squibb in the 2nd quarter valued at about $42,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group lifted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective for the company. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $52.38.

Bristol-Myers Squibb Trading Up 0.3 %

NYSE BMY opened at $52.68 on Thursday. The firm’s 50 day moving average price is $50.98 and its two-hundred day moving average price is $46.48. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $55.03. The stock has a market cap of $106.79 billion, a price-to-earnings ratio of -16.99, a PEG ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.56%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.